Saturday , August 13 2022

IPN scientists are designing new drugs against Alzheimer's disease


Scientists of the National Polytechnic Institute (IPN) High Medical School (ESM), they designed a complex multiple target which acts on three pharmacological targets Alzheimer's disease.

The drug is evaluated by computer in cell lines and on animal models, and found to have very similar effects with a compound called galantamine, which is currently used to treat this condition in mild and moderate phases.

The product of the decade of research led by dr. Martha Cecilia Rosales Hernandez, multipurpose unit improves memory because it is able to inhibit acetylcholinesterase enzyme, increases acetylcholine within the synapse and increases neurotransmission, said the expert.

The Alzheimer & apos; s – said a specialist – the disease is difficult to diagnose because it often confuses with senile dementia, although Mexico has no accurate picture of the disease, it is estimated that it affects between six and nine percent of the population over 60 years.

Blok mesta


Polytechnic researcher explained this the drug also works to prevent the onset of senile plaque, inhibiting the aggregation of Beta-amyloid proteins and Beta secretase enzyme, which is responsible for the hydrolysis of the amyloid precursor protein in fragments that are known as BETA-amyloid peptides, are combined to form plaques.

Dr. Rosales Hernandez said the product was developed to prevent the aggregation of the beta-amyloid peptide, which produces senile plaques and some proinflammatory molecules that cause the production of reactive oxygen species.

In order to understand the behavior of beta-amyloid peptide, IPN researchers design molecules in molecules (calculating) interacting with it, which allows them to have specific structures aimed at avoiding peptide aggregation. Functioning of the molecule is evaluated using calculating tools and three or five best activities are selected. This process saves time and money in research.

When we compare this multilayer compound with galanthamine, we affirm that it has very similar effects. So far, there are no medicines that attack several targets, said Dr. Martha Rosales and pointed out that pharmacokinetic tests, toxicity studies, and lethal doses in animals still required before moving into the clinical phase.

He explained this Alzheimer's is a multiple neurodegenerative process in the nervous system centrally characterized by the progressive loss of short-term memory and attention, and then the participation of other cognitive skills such as language, abstract thinking, critical interpretation and recognition of places or people.

A Polytechnic researcher explained that at the histopathological level there are two specific markers that characterize them Alzheimer & apos; s, are protein aggregates: neurofibrillary tangles located within neurons, the number of which is directly related to the intensity of dementia and are mostly composed of Tau proteins.

In the meantime, neurotic plaques or senile plates (highly toxic to neurons) have deteriorated deposits of Beta-amyloid proteins that are formed extracellularly in the intraneuronal spaces of gray matter of the brain, mainly in the hippocampus and prefrontal cortex involved in memory and emotional control.

He pointed out that even when they tested a multi-target compound continues to search for other possible drugs that help to cure this disease which, according to the World Health Organization (WHO), is the fifth cause of death in the world, and if this trend continues, it is predicted to be one of the three leading causes of death in the world for 30 years.

Source link